5
Clinical Trials associated with Autologous Adipose tissue derived Mesenchymal Stem Cells(R Bio)A 48-Weeks, Phase 2b/3a, Double-Blind, Randomized, Placebo Controlled, Multi-center, Superiority Study to Evaluate the Efficacy and Safety of JointStem, Autologous Adipose Tissue Derived Mesenchymal Stem Cells in Patients Diagnosed as Knee Osteoarthritis
This study is a double-blind, randomized, placebo controlled, multi-center, superiority study to evaluate the efficacy and safety of JointStem, autologous adipose tissue derived mesenchymal stem cells (AdMSC), in patients diagnosed as knee osteoarthritis. Following a 2-week screening period, approximately 140 subjects will be randomly assigned into one of the following two arms in a 1:1 ratio (1 JointStem : 1 Placebo). After each subject completes 48-Weeks visit (Visit 8) and the data management team confirms all individual data have no issue, the individual database will be locked and the blinding will be open for the statistical analysis.
Evaluation of the safety and feasibility of intra-arterial injection of autologous stem cells derived from adipose tissue in stroke patients.
Start Date21 Dec 2016 |
Sponsor / Collaborator- |
Clinical research (COPD) using autologous fat tissue from the mesenchymal stem cells - Clinical research (COPD) using autologous fat tissue from the mesenchymal stem cells
Start Date29 Jul 2016 |
Sponsor / Collaborator- |
100 Clinical Results associated with Autologous Adipose tissue derived Mesenchymal Stem Cells(R Bio)
100 Translational Medicine associated with Autologous Adipose tissue derived Mesenchymal Stem Cells(R Bio)
100 Patents (Medical) associated with Autologous Adipose tissue derived Mesenchymal Stem Cells(R Bio)
100 Deals associated with Autologous Adipose tissue derived Mesenchymal Stem Cells(R Bio)